Home › Employers › Safrel Pharmaceuticals, LLC
Safrel Pharmaceuticals, LLC: H-1B salaries and sponsorship
Safrel Pharmaceuticals, LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $60,902.
Does Safrel Pharmaceuticals, LLC sponsor H-1B visas?
Safrel Pharmaceuticals, LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 4, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Quality Assurance Specialist | 1 | $48,942 |
| Quality Control and Production Specialist | 1 | $60,902 |
| Production and Maintenance Engineer | 1 | $69,805 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 3 | $60,902 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Quality Control and Production Specialist | $60,902 Level I | Cranbury, NJ | Jun 4, 2024 | Oct 1, 2024 | Certified |
| Production and Maintenance Engineer | $69,805 Level I | Cranbury, NJ | Jun 4, 2024 | Oct 1, 2024 | Certified |
| Quality Assurance Specialist | $48,942 Level I | Cranbury, NJ | Jun 4, 2024 | Oct 1, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).